Emmessar Biotech & Nutrition Share Price
24.63+0.33 (+1.36%)
-7.72% past 1 Year
Emmessar Biotech & Nutrition Ltd is engaged in the manufacture of Super Speciality Fine Chemicals. The company has also diversified into the field of Biotechnology & Healthcare.Their product range includes
Corporate filings & documents
Announcements
Please refer attachment
1 week agoPlease refer attachment
1 week agoPlease refer attachment
3 weeks agoPlease refer attachment
3 weeks agoPlease refer attachement
4 weeks agoPlease refer attachement
4 weeks agoPlease refer attachement
4 weeks agoPlease refer attachement
4 weeks agoEmmessar Biotech & Nutrition Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 inter alia to consider and approve please refer attachment
1 month agoEmmessar Biotech & Nutrition Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 inter alia to consider and approve please refer attachment
1 month agoplease refer attachment
1 month agoplease refer attachment
1 month agoPlease refer attachment
1 month agoplease refer attachment
2 months agoplease refer attachment
2 months agoPlease refer attachment
3 months agoplease refer attachment
3 months agoplease refer attachment
3 months agoplease refer attachement
3 months agoplease refer attachement
3 months agoplease refer attachment
3 months agoplease refer attachment
3 months agoEmmessar Biotech & Nutrition Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2026 inter alia to consider and approve please refer attachement
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Emmessar Biotech & Nutrition Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24110MH1992PLC065942</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Priyanka Sharma <br/> Designation: Company Secretary <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Jeyavel Nadar <br/> Designation: Chief Financial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 08/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Emmessar Biotech & Nutrition Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24110MH1992PLC065942</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Priyanka Sharma <br/> Designation: Company Secretary <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Jeyavel Nadar <br/> Designation: Chief Financial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 08/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoPlease refer attachments
4 months agoPlease refer attachment
5 months agoPlease refer attachment
5 months agoPlease refer attachment
5 months agoPlease refer attachment
5 months agoPlease refer attachment
6 months agoPlease refer attachment
6 months agoRefer attachment
6 months agoEmmessar Biotech & Nutrition Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 inter alia to consider and approve Please refer attachment
7 months agoPlease refer attachment
7 months agoRefer attachment
8 months agoPlease refer attachment
9 months agoPlease refer attachment
9 months agoPlease refer attachment
9 months agoEmmessar Biotech & Nutrition Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 inter alia to consider and approve please refer attachment
10 months agoPlease refer attachment
10 months agoPlease refer attachment
11 months agoPlease refer attachment
11 months agoPlease refer attached
11 months agoPlease refer attachment
12 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
No data available.
Company details
Registered office
Plot No. T-3/2 M I D C Area Taloja Raigad Dist Maharashtra PIN: 410208 Tel No: 022-35661373 / 35664530 Fax No: NULL Email: [email protected] Internet: www.ebnl.org
Registrars
C 101, 247 Park, LBS Marg, Vikhroli (W), Mumbai(Old Address:) C-13 Pannalal Silk Compound, L B S Marg, Bhandup Mumbai Maharashtra C 101, 247 Park LBS Marg Vikhroli (West) PIN: Tel No: +91 810 811 8484 Fax No: 91-022-49186060 Email: [email protected] Internet: https://in.mpms.mufg.com/
Management
Priyanka Sharma, Company Secretary & Compliance Officer
Srinivasa Raghavan Mathurakavi Ayyangar, Managing Director
Anuradha Srinivasa Raghavan, Non Executive Director
Sarada Srinivasa Raghavan, Non Executive Director
Jeyavel B Nadar, Executive Director & Chief Financial Officer
Milind Sitaram Desai, Non Executive Independent Director
Veeraraghavan Ranganathan, Non Executive Independent Director
Dinesh Kumar Deora, Non Executive Independent Director
Details
BSE 524768
NSE NULL
ISIN INE634B01016